RPRX Stock Analysis: Buy, Sell, or Hold?
RPRX - Royalty Pharma plc Class A Ordinary Shares
$41.68
0.82 (2.01%)
▲
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 11, 2026
9d
Get Alerted When RPRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called RPRX this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RPRX shows positive signals but monitor for confirmation. Market pricing in 1.5% growth. Moderate conviction.
💡 BUY OPPORTUNITY: RPRX shows positive signals but monitor for confirmation. Market pricing in 1.5% growth. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$56.31
Based on 7.2% avg growth
INTRINSIC VALUE TODAY
$34.96
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RPRX is currently trading at $41.68, which is considered extended relative to its 30-day fair value range of $39.15 to $40.71. The stock's valuation (Forward PE: 8.2) is in line with its historical norms (7.8). At these levels, the market is pricing in 1.5% annual earnings growth.
Technical Outlook: Technically, RPRX is in a strong uptrend. The price is approaching resistance at $41.72. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: RPRX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $48.10 (+15.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RPRX is in a strong uptrend. The price is approaching resistance at $41.72. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: RPRX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $48.10 (+15.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$39.15 -
$40.71
Company Quality Score
67/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
62.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($48.10)
- BULLISH: Expecting earnings turnaround to 1.5% growth with 7.9% revenue growth
Fair Price Analysis
30-Day Fair Range
$39.15 -
$40.71
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$38.86
Resistance Level
$41.72
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
8.15
Wall Street Target
$48.10
(+15.4%)
Revenue Growth (YoY)
7.9%
Earnings Growth (YoY)
-45.2%
Profit Margin
32.6%
Valuation Premium vs History
+1.5% premium
PE vs Historical
8.2 vs 7.8
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.5%
(market-implied from PE analysis)
1-Year Target
$42.31
(+2%)
2-Year Target
$42.94
(+3%)
3-Year Target
$43.58
(+5%)
3-Yr Target (if PE normalizes)
(PE: 8→8)
PE COMPRESSION
$41.73
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 10.3%)
$153.16
(+268%)
Base:
(SPY PE: 8.1, Growth: 10.3%)
$55.95
(+34%)
Bear:
(PE: 6.9, Growth: 10.3%)
$47.56
(+14%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (23x PE), but valuation improves significantly next year (8x PE) as earnings recover.
Trailing PE: 23.09 | Current EPS (TTM): $1.75
Bull Case
$88.90
(+113%)
Analyst growth 100.0%, PE expands to 25.4
Base Case
$80.82
(+94%)
Market implied 100.0%, PE stable at 23.1
Bear Case
$27.48
(-34%)
Severe decline -20.0%, PE contracts to 19.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Last updated: January 31, 2026 11:31 PM ET
Data refreshes hourly during market hours. Next update: 12:31 AM
Data refreshes hourly during market hours. Next update: 12:31 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RPRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$404 | 63 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$210 | 57 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
Advanced RPRX Option Strategies
Professional options setups generated by AI based on today's RPRX price and gamma walls.
